Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats

International Journal of Biological Sciences

Volumn 5, Issue 5, 2009, Pages 466-473

  El Sayyad, Hassan I ^a   Ismail, Mohamed F ^a   Shalaby, F M ^a   Abou El Magd, R F ^a   Gaur, Rajiv L ^a   Fernando, Augusta ^a   Raj, Madhwa H G ^b   Ouhtit, Allal ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Mansoura University   (Egypt)

Author keywords

5 Fu; Chemotherapy; Cisplatin; Doxorubicin; Hepatotoxicity; Rat liver

Indexed keywords

RATTUS;

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FLUOROURACIL;

ANIMAL; ARTICLE; BODY WEIGHT; DRUG EFFECT; LIVER; MALE; ORGAN SIZE; RAT; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CISPLATIN; DOXORUBICIN; FLUOROURACIL; LIVER; MALE; ORGAN SIZE; RATS;

EID: 70249146563     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.5.466     Document Type: Article

References (34)

1. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of fol-low-up. N Engl J Med. 1995; 332:901-906.
2. de Graaf H, Willemse PH, Bong SB, Piersma H, Tjabbes T, van Veelen H, Coenen JL, de Vries EG. Dose intensity of standard adjuvant CSF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. Oncology. 1996; 53:289-294
3. Yuan JN, Chao Y, Lee WP, Li CP, Lee RC, Chang FY, Yen SH, Lee SD, Whang-Peng J. Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for pa-tients with advanced hepatocellular carcinoma. Med Oncol. 2008; 25:201-6.
4. Lin CC, Hsu CH, Huang CY, Cheng AL, Chen J, Vogelzang NJ, Pu YS. Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothe-lial carcinoma: an effective regimen with low toxicity. Cancer. 2006; 106:1269-75.
5. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ. A randomized phase III study of doxoru-bicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemo-therapy for unresectable hepatocellular carcinoma. J Natl Can-cer Inst. 2005; 97:1532-8.
6. Ajani JA. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer. 2008; 113:945-55.
7. Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008; 19:1450-7.
8. Alvarez-Cabellos R, Garcia-Carbonero R, Garcia-Lacalle C, Gomez P, Tercero A, Sanchez D, Paz-Ares L. Fluorouracil-based chemotherapy in patients with gastrointestinal malignancies: influence of nutritional folate status on toxicity. J Chemother. 2007; 19:744-9.
9. Pal S, Sengupta Sadhu A, Patra S, Mukherjea KK. Histological vis a vis biochemical assessment on the toxic level and anti-neoplastic efficacy of a synthetic drug Pt ATP on experimental animal models. J Exp Clin Cancer Res. 2008; 27:68.
10. Kim S.H., Hong K.O., Chung W., Hwang J.K & Park K. Abrogation of cisplatin-induced hepatotoxicity in mice by xanthorrhizol is related to its effect on the regulation of gene transcription. Toxicology and Applied Pharmacology; 2004; 196:346-355.
11. Kim KS, Joseph B, Inada M, Gupta S. Regulation of hepatocyte engraftment and proliferation after cytotoxic drug-induced perturbation of the rat liver. Transplantation. 2005; 80:653-9.
12. Bessler H, Straussberg R, Alexandrova S, Beilin B, Djaldetti M, Hart J. Effect of oral chemotherapy on the mitochondrial size of mouse intestinal cells. Cancer Chemother Pharmacol. 1996; 38:35-8.
13. Venkatesan PN, Rajendran P, Ekambaram G, Sakthisekaran D. Combination therapeutic effect of cisplatin along with Solanum trilobatum on benzo(a)pyrene induced experimental lung car-cinogenesis. Nat Prod Res. 2008; 22:1094-106.
14. Yilmaz HR, Sogut S, Ozyurt B, Ozugurlu F, Sahin S, Isik B, Uz E, Ozyurt H. The activities of liver adenosine deaminase, xanthine oxidase, catalase, superoxide dismutase enzymes and the levels of malondialdehyde and nitric oxide after cisplatin toxicity in rats: protective effect of caffeic acid phenethyl ester. Toxicol Ind Health. 2005; 21:67-73.
15. Yüce A, Ateşşahin A, Ceribaşi AO, Aksakal M. Ellagic acid prevents cisplatin-induced oxidative stress in liver and heart tissue of rats. Basic Clin Pharmacol Toxicol. 2007; 101:345-9.
16. Valls-Belles V, Torres Mdel C, Boix L, Muñiz P, Gonzalez-Sanjose ML, Codoñer-Franch P. alpha-Tocopherol, MDA-HNE and 8-OHdG levels in liver and heart mitochondria of adriamycin-treated rats fed with alcohol-free beer. Toxicology. 2008; 249:97-101.
17. Ray S, Roy K, Sengupta C. In vitro evaluation of protective effects of ascorbic acid and water extract of Spirulina plantesis (blue green algae) on 5-fluorouracil-induced lipid peroxidation. Acta Pol Pharm. 2007; 64:335-44.
18. Burmeister BH, Walpole ET, D'Arcy N, Burmeister EA, Cox S, Thomson DB, Harvey JA, Smithers BM. A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer. Invest New Drugs. 2008; [Epub ahead of print]
19. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001; 6:162-76.
20. th ed. New York: John Wiley and Sons Inc; 1997:553.
21. Stewart DJ, Benjamin RS, Luna M.: Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol 1982; 10:51-54.
22. Liao Y, Lu X, Lu C, Li G, Jin Y, Tang H. Selection of agents for prevention of cisplatin-induced hepatotoxicity. Pharmacol Res 2008; 57:125-31.
23. Moriya A, Hyodo I, Nishina T, Imaoka H, Imagawa A, Doi T, Endo H, Tanimizu M, Tajiri H. Extensive liver metastasis of gastric cancer effectively treated by hepatic arterial infusion of 5-fluorouracil/cisplatin. Gastric Cancer 2000; 3:110-115.
24. Farber E. Programmed cell death: Necrosis versus apoptosis. Mod Pathol 1994;7:605-609.
25. Ledda-Columbano GM, Coni P, Curto M, Giacomini L, Faa G, Oliverio S, Piacentini M, Columbano A. Induction of two different modes of cell death, apoptosis and necrosis, in rat liver after a single dose of thioacetamide. Am J Pathol 1991; 139:1099-1109.
26. Knight TR, Fariss MW, Farhood A, Jaeschke H. Role of lipid peroxidation as a mechanism of liver injury after acetaminophen overdose in mice. Toxicol Sci. 2003; 76:229-36.
27. Kishimoto S, Miyazawa K, Terakawa Y, Ashikari H, Ohtani A, Fukushima S, Takeuchi Y. Cytotoxicity ofcis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-plati num (II) suspended in Lipiodol in a newly established cis-platin-resistant rat hepatoma cell line. Jpn J Cancer Res 2000; 91:1326-32.
28. Łubgan D, Marczak A, Walczak M, Distel L, Jóźwiak Z. Pharmacological mechanisms of Doxorubicin activity (DOX) current state of knowledge]. Przegl Lek 2006; 63:782-8.
29. Lai PS, Lou PJ, Peng CL, Pai CL, Yen WN, Huang MY, Young TH, Shieh MJ. Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy. J Control Release 2007; 122:39-46.
30. Bartoszek A. Metabolic activation of adriamycin by NADPH-cytochrome P450 reductase; overview of its biological and biochemical effects. Acta Biochim Pol 2002; 49:323-31.
31. Saad SY, Najja TA, Al-Rikabi AC. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res 2001; 43:211-218.
32. Deepa PR, Varalakshmi P. Protective effect of low molecular weight heparin on oxidative injury and cellular abnormalities in adriamycin-induced cardiac and hepatic toxicity. Chemico-Biological Interactions 2003; 146:201-210.
33. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001; 6:162-76.
34. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94:274-86.